Stoke Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stoke Therapeutics, Inc. (STOK) on April 7, 2026, covering events occurring on April 3, 2026. The filing reports a change in the composition of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $45,000 for the new director.
- Initial Stock Option Grant: 30,782 shares with a target grant date fair value of approximately $724,000.
- Vesting Schedule: Twelve substantially equal quarterly installments.
Material Changes
The Board of Directors increased its size from nine to ten members. G. Clare Kahn, Ph.D., was appointed as a Class I director effective immediately. Dr. Kahn was also appointed to the Nominating and Corporate Governance Committee and named chairperson of the Research and Development Committee. The Board determined Dr. Kahn qualifies as an independent director.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No risks, contingencies, or unusual items were disclosed in this report. The appointment was made following the recommendation of the Nominating and Corporate Governance Committee, with no undisclosed arrangements or material interests identified.
Key Facts for Investor Verification
- Verify the impact of the new Board composition on the Company's strategic direction, particularly regarding the Research and Development Committee.
- Confirm the total number of outstanding shares and the dilution effect of the 30,782 new stock options granted.
- Review the full text of the press release (Exhibit 99.1) for additional context on Dr. Kahn's background and qualifications.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-K or 10-Q for financial status.